Medivir AB · OMXSTO:MVIR
Medivir AB — Life Science Investor Conference Copenhagen 2019
27 slides from Medivir AB's conference presentation, Sep 18, 2019
Slide 1: Life Science Investor Conference Copenhagen
LIFE SCIENCE INVESTOR CONFERENCE COPENHAGEN SEPTEMBER 18, 2019
Slide 2: Important notice
Important notice You must read the following before continuing. The following applies to this document and the information provided in this presentation by Medivir AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection wit
Slide 3: About Medivir
About Medivir • Founded in 1988 • Listed on Nasdaq Stockholm • Market cap around 590 million SEK, cash position at Q2-19: 192 million SEK • Has developed two drugs from idea to market: Xerclear and Olysio • Has established over 20 partnerships that generated over 400 million USD • Current focus: onc
Slide 4: Experienced leadership
Experienced leadership Uli Hacksell, PhD; CEO Uppsala U, Astra, ACADIA Magnus Christensen, MBA; CFO Linda Basse, MD; PhD; CMO O’Learys Trademark, ICA Sverige, HKScan Abbott, Topo Target, Genmab, Zealand Christina Herder, PhD; COO Rikard Höse, MD; Med Dir. Pharmacia, Biovitrum Karolinska U Hospital,
Slide 5: Medivir – Oncology focused biotech with major upside
Medivir – Oncology focused biotech with major upside CLINICAL DEVELOPMENT • Birinapant/Keytruda® combination: Ongoing phase II MSS CRC o Interim data in Q4-19 • MIV-818: Ongoing phase I study in liver cancer o Early proof of concept in phase Ia (Q2-19) o Phase Ib to start in Q4-19 • Remetinostat: On
Slide 6: Broad and robust pipeline
Broad and robust pipeline PROJECT & MECHANISM DISEASE AREA RESEARCH PRECLINICAL PHASE I PHASE II PHASE III EXCLUSIVITY Cutaneous T-cell lymphoma (MF) Remetinostat IP: 2034 HDAC INHIBITOR (TOPICAL) Basal cell carcinoma1) IP: 2034 Birinapant Solid tumors IP: 2034 SMAC MIMETIC (INTRAVENOUS) (combo with
Slide 7: Remetinostat for early-stage MF cutaneous T-cell lymphoma
Remetinostat for early-stage MF cutaneous T-cell lymphoma Slide 7
Slide 8: MF-CTCL: orphan blood cancer indication
MF-CTCL: orphan blood cancer indication Cutaneous T-cell lymphoma (CTCL) affects lymphocytes (cells belonging to the immune defense system) located in the skin and typically has a chronic course. • CTCL is a rare form of non-Hodgkin lymphoma primarily present in the skin. Mycosis fungoides (MF) is t
Slide 9: Remetinostat: for treatment of early stage MF-CTCL
Remetinostat: for treatment of early stage MF-CTCL • Remetinostat is a histone deacetylase (HDAC) inhibitor • Remetinostat’s unique chemistry and topical formulation provides for activity in skin and rapid degradation in blood • Approved HDAC inhibitors not used in early- stage MF-CTCL patients • US
Slide 10: Remetinostat: clinical proof-of-concept phase II MF-CTCL study
Remetinostat: clinical proof-of-concept phase II MF-CTCL study Twelve months phase II data shows reduction in both lesions and severe itch Dose 1% 0.5% 1% 1x/day 2x/day 2x/day n=20 n=20 n=20 Lesion responses1 20% 25% 40% Well tolerated: • No HDAC inhibitor-associated systemic adverse events Patients
Slide 11: Remetinostat: next steps
Remetinostat: next steps • Medivir has defined a phase III design based on the requirements clarified by the FDA • One phase III study expected to be sufficient for FDA • Phase III study will enroll treatment-experienced patients • Medivir seeks to identify a business partner for the further develop
Slide 12: Remetinostat for basal cell carcinoma
Remetinostat for basal cell carcinoma Slide 12
Slide 13: Remetinostat: interim phase II BCC data presented at SID 2019
Remetinostat: interim phase II BCC data presented at SID 2019* Basal cell carcinoma • The most common form of cancer in humans occurring in the skin • Surgery is standard of care, but there is a need for efficacious and safe treatments when surgery is impractical, e.g. multiple lesions and/or diffic
Slide 14: Birinapant: Uniquely potent against selected solid tumors
Birinapant: Uniquely potent against selected solid tumors Slide 14
Slide 15: Solid tumors: large unmet medical needs
Solid tumors: large unmet medical needs Many patients with solid tumors have few or no options and are in need of effective medicines to extend life. The immuno-oncology medicine Keytruda® on its own is not sufficiently effective in treatment of certain solid tumors. Colorectal cancer indication (CR
Slide 16: Birinapant/Keytruda studied in cancer patients with solid tumors
Birinapant/Keytruda® studied in cancer patients with solid tumors • Birinapant, a bivalent SMAC mimetic, enables tumor cell death and augments the immune system • Great potential to improve treatment of cancers when combined with immuno-therapy • Ongoing collaboration with Merck for a phase I/II com
Slide 17: MIV-818: Nucleotide prodrug for the treatment of liver cancer
MIV-818: Nucleotide prodrug for the treatment of liver cancer Slide 17
Slide 18: Primary liver cancer: hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Primary liver cancer : hepatocellular carcinoma and intrahepatic cholangiocarcinoma • Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide o Estimated new cases 2018: Asia: 610,000; US: 42,000; EU: 82,000; Sweden: 550 o Orphan disease in Western market
Slide 19: MIV-818: prodrug for enhanced efficacy and safety in liver cancer therapy
MIV-818: prodrug for enhanced efficacy and safety in liver cancer therapy Troxacitabine MIV-818 Medivir • Clinically active but failed due prodrug • Enhanced activity to systemic dose-limiting technology • Selectivity for cancer toxicities • Improved delivery to the liver Phase I RP2D • Oral adminis
Slide 20: MIV-818: Proof-of-concept phase Ia data
MIV-818: Proof-of-concept phase Ia data • Data from six patients with advanced liver cancer and treated with escalated doses were analized • MIV-818 was well tolerated. Lowering of blood counts in patient six suggests that highest dose is close to starting dose for phase Ib • Clear signs of effect,
Slide 21: MIV-828: For acute myeloid leukemia
MIV-828: For acute myeloid leukemia Slide 21
Slide 22: MIV-828: Summary
MIV-828: Summary Acute myeloid leukemia (AML) leads to an overproduction of abnormal immature cells in the bone marrow and prevents development of normal blood cells, which could lead to anemia, bleeding episodes and a high susceptibility for severe infections. • Expected new cases 2018: US: 19,50
Slide 23: MIV-711: Cathepsin K inhibitor with FDA fast track status
MIV-711: Cathepsin K inhibitor with FDA fast track status Slide 23
Slide 24: Osteoarthritis (OA): the most common form of joint disease
Osteoarthritis (OA): the most common form of joint disease • Affects ~240m adults worldwide Cathepsin K protease is involved in the breakdown of collagen I in both bone and collagen II in cartilage • Prevalence increasing due to aging population and obesity epidemic Healthy knee OA knee • Current tr
Slide 25: MIV-711: positive effects on joint structure and signals of benefit on clinical symptoms
MIV-711: positive effects on joint structure and signals of benefit on clinical symptoms • Study design (MIV-711-201): 3 arms, 26 weeks treatment • Study design (MIV-711-202): 200 mg MIV-711, 26 additional weeks MIV-711-201: Change from baseline vs week 26 Placebo MIV-711 100 mg QD MIV-711 200 mg QD
Slide 26: Milestones
ef 3%. a @° 7 ones Milest
Slide 27: Medivir - recent and upcoming milestones
Medivir - recent and upcoming milestones MIV-828: CD nomination Q4 2018 Birinapant/Keytruda®: completion of phase I Q4 2018 MIV-818: Start of phase Ia Q4 2018 Remetinostat: EoP2 meeting with FDA Q4 2018 Birinapant/Keytruda®: start of phase II Q4 2018 MIV-818: POC in phase Ia Q2 2019 New organization
Medivir — Life Science Investor Conference Copenhagen 2019 on 6ix